WO2002078717A3 - Compositions and methods for reducing rna virus pathogenicity - Google Patents

Compositions and methods for reducing rna virus pathogenicity Download PDF

Info

Publication number
WO2002078717A3
WO2002078717A3 PCT/EP2002/003025 EP0203025W WO02078717A3 WO 2002078717 A3 WO2002078717 A3 WO 2002078717A3 EP 0203025 W EP0203025 W EP 0203025W WO 02078717 A3 WO02078717 A3 WO 02078717A3
Authority
WO
WIPO (PCT)
Prior art keywords
compositions
methods
rna virus
virus pathogenicity
reducing rna
Prior art date
Application number
PCT/EP2002/003025
Other languages
French (fr)
Other versions
WO2002078717A2 (en
Inventor
Melinda Beck
Bruce German
Orville Levander
Dael Peter Van
Original Assignee
Nestle Sa
Univ North Carolina
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nestle Sa, Univ North Carolina filed Critical Nestle Sa
Priority to AU2002308169A priority Critical patent/AU2002308169A1/en
Publication of WO2002078717A2 publication Critical patent/WO2002078717A2/en
Publication of WO2002078717A3 publication Critical patent/WO2002078717A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention provides methods and compositions for treating and/or preventing RNA viral diseases. In an embodiment, the present invention provides a method for treating RNA viral infections comprising the step of administering to a individual having an RNA viral infection, a therapeutically effective amount of selenium.
PCT/EP2002/003025 2001-03-28 2002-03-26 Compositions and methods for reducing rna virus pathogenicity WO2002078717A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2002308169A AU2002308169A1 (en) 2001-03-28 2002-03-26 Compositions and methods for reducing rna virus pathogenicity

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US81938701A 2001-03-28 2001-03-28
US09/819,387 2001-03-28

Publications (2)

Publication Number Publication Date
WO2002078717A2 WO2002078717A2 (en) 2002-10-10
WO2002078717A3 true WO2002078717A3 (en) 2003-08-28

Family

ID=25228011

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2002/003025 WO2002078717A2 (en) 2001-03-28 2002-03-26 Compositions and methods for reducing rna virus pathogenicity

Country Status (2)

Country Link
AU (1) AU2002308169A1 (en)
WO (1) WO2002078717A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111568921A (en) * 2020-04-20 2020-08-25 奥格生物技术（六安）有限公司 Novel selenium preparation formula for promoting recovery of patients with coronavirus and preparation method thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0596717A1 (en) * 1992-11-05 1994-05-11 Chandra Consultants Nutritional supplement for the elderly
US5770217A (en) * 1997-07-02 1998-06-23 Atlatl, Inc. Dietary supplement for hematological, immune and appetite enhancement
WO1998030228A1 (en) * 1997-01-13 1998-07-16 Emory University Compounds and their combinations for the treatment of influenza infection

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0596717A1 (en) * 1992-11-05 1994-05-11 Chandra Consultants Nutritional supplement for the elderly
WO1998030228A1 (en) * 1997-01-13 1998-07-16 Emory University Compounds and their combinations for the treatment of influenza infection
US5770217A (en) * 1997-07-02 1998-06-23 Atlatl, Inc. Dietary supplement for hematological, immune and appetite enhancement

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
F.GIRODON E.A.: "Impact of trace elements and vitamin supplementation on immunity and infections in institutionalized elderly patients", ARCHIVES ON INTERNAL MEDICINE, vol. 159, no. 7, 1999, pages 748 - 754, XP008013803 *

Also Published As

Publication number Publication date
WO2002078717A2 (en) 2002-10-10
AU2002308169A1 (en) 2002-10-15

Similar Documents

Publication Publication Date Title
WO2001077091A3 (en) Ns5b hcv polymerase inhibitors
WO2001068116A3 (en) Immunostimulatory polynucleotide sequences for use in preventing and treating respiratory viral infections
EA200201263A1 (en) METHODS OF TREATING INFECTIONS, CAUSED BY THE HEPATITIS DELTA VIRUS, USING β-L-2'-DEOXYNUCLEOSIDES
WO2003093290A8 (en) Nucleoside derivatives for treating hepatitis c virus infection
WO2004028481A3 (en) Nucleoside derivatives for treating hepatitis c virus infection
WO2001090121A3 (en) Methods and compositions for treating hepatitis c virus
WO2003099110A3 (en) Herbs and herbal combinations useful for the treatment of microbial infections
WO2004096818A3 (en) Method and compositions for identifying anti-hiv therapeutic compounds
WO2003053349A3 (en) Inhibitors of hepatitis c virus
IL157652A (en) Metalloproteinase inhibitors, compositions comprising them and uses thereof for the preparation of medicaments for treating diseases or conditions mediated by metalloproteinase enzymes
WO2004107956A3 (en) Methods and devices for the treatment of skin lesions
ID27787A (en) COMPOUND, COMPOSITION AND METHODS FOR TREATMENT OR PREVENTION OF INFECTIONS CAUSED BY VIRUSES AND RELATED DISEASES
WO2005002526A3 (en) Method and compositions for treatment of viral infections
WO2004085682A3 (en) Caspase inhibitors, especially caspase 3 inhibitors, for the treatment of influenza
WO2005028496A3 (en) Vaccine for treatment and prevention of herpes simplex virus infection
AU2002346686A1 (en) Compositions and method for treating hepatitis virus infection
WO2003059385A3 (en) Hiv vaccine and method of use
WO2003015708A8 (en) Composition and method for treating hiv infection
WO2002062959A3 (en) Hepatitis b virus treatment
AUPQ761200A0 (en) Compositions and methods for treatment of mucosal infections
WO2007121491A8 (en) Hcv vaccinations
AU2002219881A1 (en) Methods and compositions for the treatment of human immunodeficiency virus infection
ZA991029B (en) Composition and methods for treatment of hiv infections.
WO2003053332A3 (en) Composition and method for treating viral infection
WO2004030631A3 (en) Anti-cancer and anti-infectious disease compositions and methods for using same

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP